|
Colombia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Colombia Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Colombia.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Colombian pharmaceutical and healthcare industry.
Competitive intelligence, Colombian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Colombian market.
The Colombia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Colombia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Colombian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Colombia to test other views – a key input for successful budgeting and strategic business planning in the Colombian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Colombian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Colombia.
- Exploit The Latest Competitive Colombian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Colombia.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Colombia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Colombia Pharmaceutical And Healthcare Industry SWOT |
| Colombia Political SWOT Analysis |
| Colombia Economic SWOT Analysis |
| Colombia Business Environment SWOT Analysis |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Americas Pharmaceutical Business Environment Ratings for Q209 |
| Limits To Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Colombia – Market Summary |
| Regulatory Regime |
| Intellectual Property Environment |
| Counterfeit Pharmaceuticals |
| Proposed US Free Trade Agreement |
| Table: Colombia-US FTA Mechanisms Relevant To IP |
| Pricing And Reimbursement Issues |
| Other Regulatory Issues |
Chapter - Industry Developments |
| Epidemiology |
| Healthcare Sector |
| Healthcare Insurance |
| Healthcare Insurance Funding |
| Pharmaceutical Sector |
| Recent Pharmaceutical Company Developments |
| Clinical Trials |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Colombia - Drug Market Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Colombia - Health Expenditure Trends, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Colombia - Economic Activity |
| Prescription Market Forecasts |
| Table: Colombia - Prescription Market Indicators, Historical Data and Forecasts (COPmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Colombia - Patented Market Indicators, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: Colombia - Generic Market Trends, Historical Data and Forecasts |
| OTC Market Forecasts |
| Table: Colombia - OTC Market Indicators, Historical Data and Forecasts (COPmn unless otherwise stated) |
| Pharmaceutical Trade Forecasts |
| Table: Colombia - Pharmaceuticals Trade Indicators, Historical Data and Forecasts (US$mn) |
| Medical Device Market Forecast |
| Table: Colombia – Medical Devices Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Colombia – Other Healthcare Data Indicators, Historical Data and Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Monitor |
| Leading Multinationals |
| GlaxoSmithKline (GSK) |
| Pfizer |
| Merck & Co |
| Sanofi-Aventis |
| Novartis |
| Indigenous Manufacturers |
| Tecnoquímicas |
| Lafrancol |
| Laboratorios Brussié |
Chapter - Country Snapshot: Colombia Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Colombia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s updated Business Environment Ranking table for the Americas, Colombia’s score has remained the same, again ranking the country fifth out of the 10 major markets in the region. While the rising population numbers and a steady forecast market growth represent considerable draws for foreign companies, the persistent problems regarding its intellectual property (IP) environment – as well as the higher attractiveness of other larger and better regulated Latin American markets - will continue to hamper foreign direct investment (FDI) over the coming years.
Colombia’s drug market compound annual growth rate (CAGR) in local currency terms is forecast at a solid 11.56%, similar to the US dollar CAGR, which is expected at 12.04%. In theory, the future ratification of the penned Free Trade Agreement (FTA) by the US should provide a legal basis to continue to improve enforcement to meet its treaty obligations, although continued delays to the ratification of the deal are breeding uncertainty.
On a positive note, there has been an increase in the presence of non-profit organisations addressing Colombia's healthcare needs, to the tune of US$81mn in 2005. In light of mounting evidence of the country's exposure to the global economic downturn, BMI's Country Risk team believes Colombia will be unable to escape a recession in 2009. The GDP growth forecast has been revised downwards, from 2.9% and 4.5% in 2009 and 2010, respectively, to 2.1% and 3.9%. This will further reduce the government's focus on improving the country's healthcare systems, leading to more non-profit institutions entering the country. In fact, given that price rises in private healthcare are the second-largest component of top-line inflation figures, alternative funding sources will be crucial for ensuring adequate access to healthcare and ensuring that certain social groups (such as indigenous and female population) are not further disadvantaged.
Colombian private health insurance firms have recently been criticised for failing to provide care for HIV/AIDS patients. The United Nations Program on AIDS (UNAIDS) has expressed serious concerns over the absence of a transparent national strategy that has left private health insurers with little or no incentives to provide relevant treatments for affected patients. Nevertheless, according to the latest report by UNAIDS on the global HIV/AIDS epidemic, Latin America is performing better in terms of scaling up access to antiretroviral (ARV) drugs compared with rates of coverage in other low- and middle-income countries. However, a perception that the price of treatment in Latin America is high compared with other regions is leading to mounting pressure on Latin America's leaders to talk tough on perceived overpricing of ARVs. A number of non-governmental organisations (NGOs) have already petitioned the Colombian government to issue a compulsory licence for one ARV, following failed requests that its manufacturer voluntarily lowers the drug’s price.
|
Colombia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |